Ben R. Taylor - Feb 3, 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Financial Officer
Signature: /s/ Kyle Nelson, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Feb 3, 2025
Transactions value $: -$47,444
Form type: 4
Date filed: 2/5/2025, 04:50 PM
Previous filing: Dec 20, 2024
Next filing: Feb 20, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+35K	+4.15%	$0.00	879K	Feb 3, 2025	Direct	F1
transaction	RXRX	Class A Common Stock	Award	$0	+13.9K	+1.58%	$0.00	893K	Feb 3, 2025	Direct	F2
transaction	RXRX	Class A Common Stock	Tax liability	-$47.4K	-6.54K	-0.73%	$7.25	887K	Feb 3, 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+70K		$0.00	70K	Feb 3, 2025	Class A Common Stock	70K	$7.25	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						290K	Feb 3, 2025	Class A Common Stock	0	$0.04	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						92.7K	Feb 3, 2025	Class A Common Stock	0	$0.06	Direct	F6
holding	RXRX	Stock Option (Right to Buy)						81.2K	Feb 3, 2025	Class A Common Stock	0	$0.14	Direct	F7
holding	RXRX	Stock Option (Right to Buy)						741K	Feb 3, 2025	Class A Common Stock	0	$6.09	Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter.
F2	This RSU vested immediately upon the grant date.
F3	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F5	Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F6	Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F7	Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.
F8	1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date.